Literature DB >> 23422728

Cardiovascular mortality in schizophrenia: defining a critical period for prevention.

Vinod H Srihari1, Vivek H Phutane, Banu Ozkan, Lydia Chwastiak, Joseph C Ratliff, Scott W Woods, Cenk Tek.   

Abstract

OBJECTIVE: Better understanding of the temporal development of cardiovascular risk will permit more targeted prevention of premature cardiovascular mortality in schizophrenia.
METHODS: The sample for this analysis was drawn from referrals (between 2006 and '11) to an early psychosis clinic based in a U.S. urban community mental health center. 76 individuals with schizophrenia who were young (mean 22.4 years, SD 4.8), early course (median duration of illness 31 weeks) and with minimal prior antipsychotic exposure (median 2 weeks) were compared to age-, gender-, and race-matched peers drawn from the National Health and Nutrition Survey (2007-'08). Measures of cardiovascular risk at baseline, 6 months, and 1 year are reported.
RESULTS: While indistinguishable from peers at entry, patients suffered pervasive adverse trajectories of cardiovascular risk factors over the subsequent year. 16 of 44 initial non-smokers became nicotine dependent and none of 32 entering smokers quit. 17 patients transitioned to overweight (BMI 25-29.9, n = 3) or obese (BMI>30, n = 14) categories, while only 24 of 38 (63%) sustained normal weight over one year. Similar adverse trends in blood pressure, lipids, and fasting glucose led to an increase in prevalence of metabolic syndrome (1.31% to 5.26%). 10-year cardiovascular risk estimates showed a small and significant increase although remaining in the low risk (<10%) category.
CONCLUSIONS: The early emergence of obesity and smoking in younger schizophrenia samples provides a rational focus for primary prevention of premature cardiovascular mortality. The first year of treatment constitutes the beginning of a critical period for such preventive efforts.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23422728      PMCID: PMC3622848          DOI: 10.1016/j.schres.2013.01.014

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  22 in total

1.  Medical services for clients in community mental health centers: results from a national survey.

Authors:  Benjamin G Druss; Steven C Marcus; Jeannie Campbell; Brian Cuffel; James Harnett; Chuck Ingoglia; Barbara Mauer
Journal:  Psychiatr Serv       Date:  2008-08       Impact factor: 3.084

2.  The unchanging mortality gap for people with schizophrenia.

Authors:  Lydia A Chwastiak; Cenk Tek
Journal:  Lancet       Date:  2009-08-22       Impact factor: 79.321

3.  Public-academic partnerships: early intervention for psychotic disorders in a community mental health center.

Authors:  Vinod H Srihari; Nicholas J K Breitborde; Jessica Pollard; Cenk Tek; Leslie Hyman; Linda K Frisman; Thomas H McGlashan; Selby Jacobs; Scott W Woods
Journal:  Psychiatr Serv       Date:  2009-11       Impact factor: 3.084

4.  A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.

Authors:  Donald C Goff; Lisa M Sullivan; Joseph P McEvoy; Jonathan M Meyer; Henry A Nasrallah; Gail L Daumit; Steven Lamberti; Ralph B D'Agostino; Thomas S Stroup; Sonia Davis; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2005-09-28       Impact factor: 4.939

Review 5.  Assessing substance use disorder in persons with severe mental illness.

Authors:  R E Drake; S D Rosenberg; K T Mueser
Journal:  New Dir Ment Health Serv       Date:  1996

6.  Best practices: surveillance and management of diabetes in a CMHC population.

Authors:  Vinod H Srihari; Cenk Tek; Lydia A Chwastiak; Scott W Woods; Jeanne L Steiner
Journal:  Psychiatr Serv       Date:  2007-09       Impact factor: 3.084

Review 7.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  J Am Coll Cardiol       Date:  2004-08-04       Impact factor: 24.094

Review 8.  Early intervention in psychosis. The critical period hypothesis.

Authors:  M Birchwood; P Todd; C Jackson
Journal:  Br J Psychiatry Suppl       Date:  1998

Review 9.  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?

Authors:  Sukanta Saha; David Chant; John McGrath
Journal:  Arch Gen Psychiatry       Date:  2007-10

10.  Quality of diabetes care among adults with serious mental illness.

Authors:  Richard W Goldberg; Julie A Kreyenbuhl; Deborah R Medoff; Faith B Dickerson; Karen Wohlheiter; Li Juan Fang; Clayton H Brown; Lisa B Dixon
Journal:  Psychiatr Serv       Date:  2007-04       Impact factor: 3.084

View more
  29 in total

1.  Metabolic syndrome in antipsychotic naive African patients with severe mental illness in usual care.

Authors:  Shamima Saloojee; Jonathan K Burns; Ayesha A Motala
Journal:  Early Interv Psychiatry       Date:  2017-04-12       Impact factor: 2.732

2.  Social cognition psychometric evaluation (SCOPE) in people with early psychosis: A preliminary study.

Authors:  Kelsey A Ludwig; Amy E Pinkham; Philip D Harvey; Skylar Kelsven; David L Penn
Journal:  Schizophr Res       Date:  2017-03-14       Impact factor: 4.939

Review 3.  Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications.

Authors:  Cenk Tek; Suat Kucukgoncu; Sinan Guloksuz; Scott W Woods; Vinod H Srihari; Aniyizhai Annamalai
Journal:  Early Interv Psychiatry       Date:  2015-05-12       Impact factor: 2.732

Review 4.  Cardiovascular disease in patients with severe mental illness.

Authors:  René Ernst Nielsen; Jytte Banner; Svend Eggert Jensen
Journal:  Nat Rev Cardiol       Date:  2020-10-30       Impact factor: 32.419

Review 5.  The effects of physical exercise in schizophrenia and affective disorders.

Authors:  Berend Malchow; Daniela Reich-Erkelenz; Viola Oertel-Knöchel; Katriona Keller; Alkomiet Hasan; Andrea Schmitt; Thomas W Scheewe; Wiepke Cahn; René S Kahn; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-07-20       Impact factor: 5.270

6.  A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept.

Authors:  Cenk Tek; Joseph Ratliff; Erin Reutenauer; Rohan Ganguli; Stephanie S O'Malley
Journal:  J Clin Psychopharmacol       Date:  2014-10       Impact factor: 3.153

7.  Mortality Rates After the First Diagnosis of Psychotic Disorder in Adolescents and Young Adults.

Authors:  Gregory E Simon; Christine Stewart; Bobbi Jo Yarborough; Frances Lynch; Karen J Coleman; Arne Beck; Belinda H Operskalski; Robert B Penfold; Enid M Hunkeler
Journal:  JAMA Psychiatry       Date:  2018-03-01       Impact factor: 21.596

8.  Endurance training in patients with schizophrenia and healthy controls: differences and similarities.

Authors:  Katriona Keller-Varady; Alkomiet Hasan; Thomas Schneider-Axmann; Ursula Hillmer-Vogel; Björn Adomßent; Thomas Wobrock; Andrea Schmitt; Andree Niklas; Peter Falkai; Berend Malchow
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-11-05       Impact factor: 5.270

Review 9.  Obesity in Adolescents with Psychiatric Disorders.

Authors:  Ariana M Chao; Thomas A Wadden; Robert I Berkowitz
Journal:  Curr Psychiatry Rep       Date:  2019-01-19       Impact factor: 5.285

10.  Transforming the Treatment of Schizophrenia in the United States: The RAISE Initiative.

Authors:  Lisa B Dixon; Howard H Goldman; Vinod H Srihari; John M Kane
Journal:  Annu Rev Clin Psychol       Date:  2018-01-12       Impact factor: 18.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.